Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CLK2 | P49760 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618896 | 1.00 | TSHR (0.43) | TSHRALOX15CASP1NPSR1HSD17B10 | |
| SCHEMBL4230277 | 0.83 | RAB9A (0.48) | TSHRKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4230279 | 0.83 | RAB9A (0.48) | TSHRKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1620535 | 0.75 | KMT2A (0.51) | TSHRALOX15CASP1NPSR1HSD17B10 | |
| SCHEMBL4235082 | 0.73 | RAB9A (0.45) | TSHRKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4235081 | 0.73 | RAB9A (0.45) | TSHRKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24329669 | 0.69 | KMT2A (0.49) | TSHRKMT2ARAB9ANPC1MAPT | |
| Trifluoroacetic Acid SCHEMBL28718945 | 0.68 | TSHR (0.45) | TSHRALOX15CASP1NPSR1HSD17B10 | |
| SCHEMBL2036694 | 0.67 | ALDH1A1 (0.42) | TSHRALOX15CASP1NPSR1HSD17B10 | |
| SCHEMBL5381046 | 0.67 | KDM4E (0.69) | KMT2ARAB9ANPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653059-B2 | Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2019677-B1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-1761532-B1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110224195-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-7928112-B2 | Substituted 5,6,7,8-tetrahydropyrido[4,3-D]pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100324054-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| US-7812027-B2 | Substitued [1,2,4]triazolo[1,5-a]pyrazines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1784188-B1 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2190428-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7625888-B2 | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME CORP. | 2007-09-06 | — | — | US | disclosed |
| EP-1554280-B1 | ANTIDIABETIC BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS | MERCK & CO INC (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1784188-A2 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1761532-A1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1554280-A4 | ANTIDIABETIC BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS | MERCK & CO INC (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006023750-A2 | FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006009886-A1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014953-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-01-19 | — | — | US | disclosed |
| EP-1554280-A2 | ANTIDIABETIC BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS | Merck & Co., Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004032836-A2 | ANTIDIABETIC BETA-AMINO HETEROCYLCIC DIPEPTIDYL PEPTIDASE INHIBITORS | MERCK & CO., INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208010-A1 | Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | TSHR 3078/4885ALOX15 2974/4885CASP1 845/4885 |
| US-20060014953-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | TSHR 4702/4885ALOX15 1841/4885CASP1 1174/4885 |
| US-20100324054-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | TSHR 3840/4885ALOX15 1392/4885CASP1 1749/4885 |
| US-20110224195-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | TSHR 3814/4885ALOX15 1232/4885CASP1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.